Eli Lilly (NYSE: LLY) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose ...

Novo Nordisk and Eli Lilly will dominate the obesity drug market long-term, says Mizuho's Jared Holz Jared Holz, Mizuho, ...

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

Allurion catapulted nearly 200% early Friday after the company said it plans to test its weight-loss technology with an ...

One of Novo Nordisk's next-generation obesity shots to follow up on its success with Wegovy helped patients lose 22% of their ...

Novo Nordisk (NVO) stock jumped 12% in pre-market trading Friday after it released promising results of an early-stage weight ...

US-based pharmaceutical giant Eli Lilly is focusing on weight loss medications like Mounjaro (tirzepatide), which has proven ...

Novo Nordisk's phase 1b/2a clinical trial results revealed that their investigational drug, amycretin, led to an average ...

Novo Nordisk shares jump close to 14% on promising trial results for amycretin, a once-weekly obesity drug, signaling fierce ...

The FDA granted approval to Eli Lilly and Company’s mirikizumab-mrkz (Omvoh) for Crohn disease, expanding its treatment reach ...

We now have two FDA-approved disease-modifying treatments for Alzheimer's disease, and hundreds of clinical trials are ...

The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.